Sign in
CompletedPhase 2

Individualizing Corticosteroid Use in Pneumonia

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
24 people enrolled
Started
6 Nov 2024
Ended
29 Apr 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Dexamethasone
Record updated
5 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Hospitalized adult (≥ 18 years) patients
  • Community acquired pneumonia

Who cannot take part

  • Contraindications or unwillingness to use corticosteroids by patient or provider
  • History of adrenal insufficiency, septic shock, or another absolute indication for steroid use
  • Suspected pulmonary vasculitis or other autoimmune pulmonary disorder
  • Positive pregnancy test
  • Comfort care

Where in United States

  • Mayo Clinic - RochesterRochester, United States

About the trial

What the trial wants to find out

In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.

The 2 groups in the trial

  • Usual Care GroupNo study treatment, for comparison

    Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians.

  • Individualized dosing strategyTreatment being tested

    Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP \<50 mg/L (according to a prespecified C-reactive protein-guided dosing algorithm). Corticosteroid dose and duration were determined by serial CRP measurements The approved protocol included CRP-guided corticosteroid dosing as a prespecified contingency strategy if a clinically actionable individualized treatment rule could not be developed. The trial therefore proceeded with the CRP-guided corticosteroid strategy

    Treatment: Dexamethasone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 August 2026